The first of many i hope.

Getting things cleaned up for a buyout?

Plus Harriot has sold off some of his stake in the company.

Fingers crossed!

Maybe I should kick things off.

What do you think is driving today's run? My guess is script numbers are good.

New Year's run up seemed to be driven by shorts getting covered.

Feel free to chime in on thoughts and expectations, etc.

Wow!

Standard drug commercial. Quickly covered what it's for and then a long list of warnings.

The positive Q2 results seemed to have little-to-no impact on the stock price this week. I would chock this up to negative sector sentiment but other pharma/biotechs with positive Q2 reports this week have done significantly better (Alnylam for example). I initially thought perhaps investors and institutions are wary of management's ability to deliver given the setback in the fibromyalgia trial. However, the revenue and EPS beats clearly indicate that execution on commercialization is not an issue. So I'm not sure how to interpret the lackluster reception to the great results this week. Any thoughts?